Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
The clinical-stage oncology company said the FDA cleared its IND application for IM-1340, a potential first-in-class antibody-drug conjugate for advanced solid tumors. Immunome expects to start a Phase 1 study in the fourth quarter of 2026.
Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a pot…